Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

[1]  A. Cohen,et al.  Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis , 2016, PloS one.

[2]  A. Bianco,et al.  Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials. , 2016, Thrombosis research.

[3]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[4]  J. Mega,et al.  Duration of Anticoagulation for Venous Thromboembolic Events , 2014, Circulation.

[5]  W. Olson,et al.  Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients , 2014, Current medical research and opinion.

[6]  E. Akl,et al.  Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. , 2014, Blood.

[7]  A. Cohen.  Long-term benefits of preventing venous thromboembolic events , 2012, Current medical research and opinion.

[8]  A. Cohen,et al.  The use of rivaroxaban for short- and long-term treatment of venous thromboembolism , 2012, Thrombosis and Haemostasis.

[9]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[10]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[11]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[12]  W. Ageno,et al.  Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study) , 2011, Expert review of cardiovascular therapy.

[13]  W. Ray,et al.  An automated database case definition for serious bleeding related to oral anticoagulant use , 2011, Pharmacoepidemiology and drug safety.

[14]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[15]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[16]  J. Emmerich,et al.  Venous Thromboembolism: Risk Factors for Recurrence , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Monreal,et al.  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.

[18]  John A. Heit,et al.  The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.

[19]  C. Kearon,et al.  Natural History of Venous Thromboembolism , 2003, Circulation.

[20]  R. White,et al.  The epidemiology of venous thromboembolism. , 2003, Circulation.

[21]  H. Eriksson,et al.  Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.

[22]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .

[23]  C. Kearon.  Natural History of Venous Thromboembolism , 2001, Seminars in vascular medicine.